Tian et al. [13] found that β-glucan treatment could promote the differentiation of M-MDSCs into a more mature CD11c+F4/80+Ly6Clow population via dectin-1 pathway in vitro and inhibit the suppressive function of M-MDSCs, leading to the delayed tumor progression. Here, ITGAX is linked to neoplasm.